L&C Bio엘앤씨바이오
290650 · KOSDAQ · ₩290650 · 엘앤씨바이오
₩25,100▲ ₩150 (0.60%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 58.7% | 53.1% | 49.6% | 50.5% | 51.3% | 62.3% |
| Operating margin | 16.7% | 5.2% | 3.5% | 11.3% | 18.0% | 28.8% |
| Net margin | −128.5% | −161.7% | 195.7% | 70.2% | 8.6% | 30.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +36.1% | +18.6% | +4.7% | +31.0% | +15.1% | — |
| Operating income growth | +340.0% | +73.7% | −67.2% | −18.3% | −28.0% | — |
| Net income growth | −8.1% | −198.0% | +191.7% | +964.2% | −67.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −57.1% | −57.3% | 65.4% | 39.5% | 5.0% | 16.2% |
| Return on assets | −31.8% | −29.7% | 38.2% | 21.0% | 3.7% | 14.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 42.4% | 119.0% | 61.4% | 67.2% | 85.2% | 15.2% |
| Net debt to equity | −4.8% | 23.8% | 32.5% | 15.8% | 64.6% | −14.8% |
| Current ratio | 132.9% | 58.5% | 84.2% | 128.0% | 343.1% | 845.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: L&C Bio / 엘앤씨바이오 / 290650 / KRX:290650
Source: KRX statistical information